1
|
Sautreuil C, Lecointre M, Dalmasso J, Lebon A, Leuillier M, Janin F, Lecuyer M, Bekri S, Marret S, Laquerrière A, Brasse-Lagnel C, Gil S, Gonzalez BJ. Expression of placental CD146 is dysregulated by prenatal alcohol exposure and contributes in cortical vasculature development and positioning of vessel-associated oligodendrocytes. Front Cell Neurosci 2024; 17:1294746. [PMID: 38269113 PMCID: PMC10806802 DOI: 10.3389/fncel.2023.1294746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2023] [Accepted: 12/11/2023] [Indexed: 01/26/2024] Open
Abstract
Recent data showed that prenatal alcohol exposure (PAE) impairs the "placenta-brain" axis controlling fetal brain angiogenesis in human and preclinical models. Placental growth factor (PlGF) has been identified as a proangiogenic messenger between these two organs. CD146, a partner of the VEGFR-1/2 signalosome, is involved in placental angiogenesis and exists as a soluble circulating form. The aim of the present study was to investigate whether placental CD146 may contribute to brain vascular defects described in fetal alcohol spectrum disorder. At a physiological level, quantitative reverse transcription polymerase chain reaction experiments performed in human placenta showed that CD146 is expressed in developing villi and that membrane and soluble forms of CD146 are differentially expressed from the first trimester to term. In the mouse placenta, a similar expression pattern of CD146 was found. CD146 immunoreactivity was detected in the labyrinth zone and colocalized with CD31-positive endothelial cells. Significant amounts of soluble CD146 were quantified by ELISA in fetal blood, and the levels decreased after birth. In the fetal brain, the membrane form of CD146 was the majority and colocalized with microvessels. At a pathophysiological level, PAE induced marked dysregulation of CD146 expression. The soluble form of CD146 decreased in both placenta and fetal blood, whereas it increased in the fetal brain. Similarly, the expression of several members of the CD146 signalosome, such as VEGFR2 and PSEN, was differentially impaired between the two organs by PAE. At a functional level, targeted repression of placental CD146 by in utero electroporation (IUE) of CRISPR/Cas9 lentiviral plasmids resulted in (i) a decrease in cortical vessel density, (ii) a loss of radial vascular organization, and (iii) a reduced density of oligodendrocytes. Statistical analysis showed that the more the vasculature was impaired, the more the cortical oligodendrocyte density was reduced. Altogether, these data support that placental CD146 contributes to the proangiogenic "placenta-brain" axis and that placental CD146 dysfunction contributes to the cortical oligo-vascular development. Soluble CD146 would represent a promising placental biomarker candidate representative of alcohol-induced neurovascular defects in neonates, as recently suggested by PlGF (patents WO2016207253 and WO2018100143).
Collapse
Affiliation(s)
- Camille Sautreuil
- Rouen Université, Inserm U1245 – Team “Epigenetics and Pathophysiology of Neurodevelopmental Disorders”, Normandie Université, Normandy Centre for Genomic and Personalized Medicine, Rouen, France
| | - Maryline Lecointre
- Rouen Université, Inserm U1245 – Team “Epigenetics and Pathophysiology of Neurodevelopmental Disorders”, Normandie Université, Normandy Centre for Genomic and Personalized Medicine, Rouen, France
| | | | - Alexis Lebon
- Rouen Université, US51 HeRacLeS, PRIMACEN Platform, Faculty of Biological Sciences, Normandie Université, Mont-Saint-Aignan, France
| | | | - François Janin
- Rouen Université, Inserm U1245 – Team “Epigenetics and Pathophysiology of Neurodevelopmental Disorders”, Normandie Université, Normandy Centre for Genomic and Personalized Medicine, Rouen, France
| | - Matthieu Lecuyer
- Rouen Université, Inserm U1245 – Team “Epigenetics and Pathophysiology of Neurodevelopmental Disorders”, Normandie Université, Normandy Centre for Genomic and Personalized Medicine, Rouen, France
| | - Soumeya Bekri
- Rouen Université, Inserm U1245 – Team “Epigenetics and Pathophysiology of Neurodevelopmental Disorders”, Normandie Université, Normandy Centre for Genomic and Personalized Medicine, Rouen, France
- Rouen Université, CHU Rouen, Department of Metabolic Biochemistry, Normandie University, Rouen, France
| | - Stéphane Marret
- Rouen Université, Inserm U1245 – Team “Epigenetics and Pathophysiology of Neurodevelopmental Disorders”, Normandie Université, Normandy Centre for Genomic and Personalized Medicine, Rouen, France
- Rouen Université, CHU Rouen, Department of Neonatal Pediatrics and Intensive Care, Rouen, France
| | - Annie Laquerrière
- Rouen Université, Inserm U1245 – Team “Epigenetics and Pathophysiology of Neurodevelopmental Disorders”, Normandie Université, Normandy Centre for Genomic and Personalized Medicine, Rouen, France
- Rouen Université, CHU Rouen, Department of Pathology, Rouen Normandy Hospital, Rouen, France
| | - Carole Brasse-Lagnel
- Rouen Université, Inserm U1245 – Team “Epigenetics and Pathophysiology of Neurodevelopmental Disorders”, Normandie Université, Normandy Centre for Genomic and Personalized Medicine, Rouen, France
| | - Sophie Gil
- Université de Paris, INSERM, UMR-S 1139, 3PHM, Paris, France
| | - Bruno J. Gonzalez
- Rouen Université, Inserm U1245 – Team “Epigenetics and Pathophysiology of Neurodevelopmental Disorders”, Normandie Université, Normandy Centre for Genomic and Personalized Medicine, Rouen, France
| |
Collapse
|
2
|
Hours CM, Gil S, Gressens P. Molecular and Cellular Insights: A Focus on Glycans and the HNK1 Epitope in Autism Spectrum Disorder. Int J Mol Sci 2023; 24:15139. [PMID: 37894820 PMCID: PMC10606426 DOI: 10.3390/ijms242015139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Revised: 10/08/2023] [Accepted: 10/11/2023] [Indexed: 10/29/2023] Open
Abstract
Autism Spectrum Disorder (ASD) is a synaptic disorder with a GABA/glutamate imbalance in the perineuronal nets and structural abnormalities such as increased dendritic spines and decreased long distance connections. Specific pregnancy disorders significantly increase the risk for an ASD phenotype such as preeclampsia, preterm birth, hypoxia phenomena, and spontaneous miscarriages. They are associated with defects in the glycosylation-immune placental processes implicated in neurogenesis. Some glycans epitopes expressed in the placenta, and specifically in the extra-villous trophoblast also have predominant functions in dendritic process and synapse function. Among these, the most important are CD57 or HNK1, CD22, CD24, CD33 and CD45. They modulate the innate immune cells at the maternal-fetal interface and they promote foeto-maternal tolerance. There are many glycan-based pathways of immunosuppression. N-glycosylation pathway dysregulation has been found to be associated with autoimmune-like phenotypes and maternal-autoantibody-related (MAR) autism have been found to be associated with central, systemic and peripheric autoimmune processes. Essential molecular pathways associated with the glycan-epitopes expression have been found to be specifically dysregulated in ASD, notably the Slit/Robo, Wnt, and mTOR/RAGE signaling pathways. These modifications have important effects on major transcriptional pathways with important genetic expression consequences. These modifications lead to defects in neuronal progenitors and in the nervous system's implementation specifically, with further molecular defects in the GABA/glutamate system. Glycosylation placental processes are crucial effectors for proper maternofetal immunity and endocrine/paracrine pathways formation. Glycans/ galectins expression regulate immunity and neurulation processes with a direct link with gene expression. These need to be clearly elucidated in ASD pathophysiology.
Collapse
Affiliation(s)
- Camille M Hours
- INSERM 1141, NeuroDiderot, Neuroprotection of the Developing Brain, Université Paris Cité, 75019 Paris, France
- Service de Psychiatrie de l'Enfant et de l'Adolescent, APHP, Hôpital Robert Debré, 75019 Paris, France
| | - Sophie Gil
- INSERM 1144, Therapeutics in Neuropsychopharmacology, Université Paris Cité, 75019 Paris, France
| | - Pierre Gressens
- INSERM 1141, NeuroDiderot, Neuroprotection of the Developing Brain, Université Paris Cité, 75019 Paris, France
- Neurologie Pédiatrique, APHP, Hôpital Robert Debré, 75019 Paris, France
| |
Collapse
|
3
|
Sautreuil C, Lecointre M, Derambure C, Brasse-Lagnel C, Leroux P, Laquerrière A, Nicolas G, Gil S, Savage DD, Marret S, Marguet F, Falluel-Morel A, Gonzalez BJ. Prenatal Alcohol Exposure Impairs the Placenta-Cortex Transcriptomic Signature, Leading to Dysregulation of Angiogenic Pathways. Int J Mol Sci 2023; 24:13484. [PMID: 37686296 PMCID: PMC10488081 DOI: 10.3390/ijms241713484] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Revised: 07/31/2023] [Accepted: 08/01/2023] [Indexed: 09/10/2023] Open
Abstract
Although alcohol consumption during pregnancy is a major cause of behavioral and learning disabilities, most FASD infants are late- or even misdiagnosed due to clinician's difficulties achieving early detection of alcohol-induced neurodevelopmental impairments. Neuroplacentology has emerged as a new field of research focusing on the role of the placenta in fetal brain development. Several studies have reported that prenatal alcohol exposure (PAE) dysregulates a functional placenta-cortex axis, which is involved in the control of angiogenesis and leads to neurovascular-related defects. However, these studies were focused on PlGF, a pro-angiogenic factor. The aim of the present study is to provide the first transcriptomic "placenta-cortex" signature of the effects of PAE on fetal angiogenesis. Whole mouse genome microarrays of paired placentas and cortices were performed to establish the transcriptomic inter-organ "placenta-cortex" signature in control and PAE groups at gestational day 20. Genespring comparison of the control and PAE signatures revealed that 895 and 1501 genes were only detected in one of two placenta-cortex expression profiles, respectively. Gene ontology analysis indicated that 107 of these genes were associated with vascular development, and String protein-protein interaction analysis showed that they were associated with three functional clusters. PANTHER functional classification analysis indicated that "intercellular communication" was a significantly enriched biological process, and 27 genes were encoded for neuroactive ligand/receptors interactors. Protein validation experiments involving Western blot for one ligand-receptor couple (Agt/AGTR1/2) confirmed the transcriptomic data, and Pearson statistical analysis of paired placentas and fetal cortices revealed a negative correlation between placental Atg and cortical AGTR1, which was significantly impacted by PAE. In humans, a comparison of a 38WG control placenta with a 36WG alcohol-exposed placenta revealed low Agt immunolabeling in the syncytiotrophoblast layer of the alcohol case. In conclusion, this study establishes the first transcriptomic placenta-cortex signature of a developing mouse. The data show that PAE markedly unbalances this inter-organ signature; in particular, several ligands and/or receptors involved in the control of angiogenesis. These data support that PAE modifies the existing communication between the two organs and opens new research avenues regarding the impact of placental dysfunction on the neurovascular development of fetuses. Such a signature would present a clinical value for early diagnosis of brain defects in FASD.
Collapse
Affiliation(s)
- Camille Sautreuil
- University Rouen Normandie, INSERM U1245, Team Epigenetics and Pathophysiology of Neurodevelopmental Disorders, 76183 Rouen, France; (C.S.); (M.L.); (C.B.-L.); (P.L.); (A.L.); (S.M.); (F.M.); (A.F.-M.)
| | - Maryline Lecointre
- University Rouen Normandie, INSERM U1245, Team Epigenetics and Pathophysiology of Neurodevelopmental Disorders, 76183 Rouen, France; (C.S.); (M.L.); (C.B.-L.); (P.L.); (A.L.); (S.M.); (F.M.); (A.F.-M.)
| | - Céline Derambure
- University Rouen Normandie, INSERM U1245, Team Genetic Predisposition to Cancer, 76000 Rouen, France;
- Joint Genomics Facilities, Rouen University, 76183 Rouen, France
| | - Carole Brasse-Lagnel
- University Rouen Normandie, INSERM U1245, Team Epigenetics and Pathophysiology of Neurodevelopmental Disorders, 76183 Rouen, France; (C.S.); (M.L.); (C.B.-L.); (P.L.); (A.L.); (S.M.); (F.M.); (A.F.-M.)
| | - Philippe Leroux
- University Rouen Normandie, INSERM U1245, Team Epigenetics and Pathophysiology of Neurodevelopmental Disorders, 76183 Rouen, France; (C.S.); (M.L.); (C.B.-L.); (P.L.); (A.L.); (S.M.); (F.M.); (A.F.-M.)
| | - Annie Laquerrière
- University Rouen Normandie, INSERM U1245, Team Epigenetics and Pathophysiology of Neurodevelopmental Disorders, 76183 Rouen, France; (C.S.); (M.L.); (C.B.-L.); (P.L.); (A.L.); (S.M.); (F.M.); (A.F.-M.)
- Department of Pathology, Rouen University Hospital, 76183 Rouen, France
| | - Gaël Nicolas
- University Rouen Normandie, INSERM U1245, Team Genomics for Brain Disorders, 76183 Rouen, France;
| | - Sophie Gil
- INSERM UMR-S1144, Sorbonne Paris Cité, Université Paris Descartes, 75006 Paris, France;
| | - Daniel D. Savage
- Department of Neurosciences, School of Medicine, University of New Mexico, Albuquerque, NM 87131, USA;
| | - Stéphane Marret
- University Rouen Normandie, INSERM U1245, Team Epigenetics and Pathophysiology of Neurodevelopmental Disorders, 76183 Rouen, France; (C.S.); (M.L.); (C.B.-L.); (P.L.); (A.L.); (S.M.); (F.M.); (A.F.-M.)
- Department of Neonatal Paediatrics and Intensive Care, Rouen University Hospital, University Rouen Normandie and CHU Rouen, 76183 Rouen, France
| | - Florent Marguet
- University Rouen Normandie, INSERM U1245, Team Epigenetics and Pathophysiology of Neurodevelopmental Disorders, 76183 Rouen, France; (C.S.); (M.L.); (C.B.-L.); (P.L.); (A.L.); (S.M.); (F.M.); (A.F.-M.)
- Department of Pathology, Rouen University Hospital, 76183 Rouen, France
| | - Anthony Falluel-Morel
- University Rouen Normandie, INSERM U1245, Team Epigenetics and Pathophysiology of Neurodevelopmental Disorders, 76183 Rouen, France; (C.S.); (M.L.); (C.B.-L.); (P.L.); (A.L.); (S.M.); (F.M.); (A.F.-M.)
| | - Bruno J. Gonzalez
- University Rouen Normandie, INSERM U1245, Team Epigenetics and Pathophysiology of Neurodevelopmental Disorders, 76183 Rouen, France; (C.S.); (M.L.); (C.B.-L.); (P.L.); (A.L.); (S.M.); (F.M.); (A.F.-M.)
| |
Collapse
|
4
|
Jiménez-Fonseca P, Sastre J, García-Alfonso P, Gómez-España MA, Salud A, Gil S, Rivera F, Reina JJ, Quintero G, Valladares-Ayerbes M, Safont MJ, La Casta A, Robles-Díaz L, García-Paredes B, López López R, Guillot M, Gallego J, Alonso-Orduña V, Diaz-Rubio E, Aranda E. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials. Clin Colorectal Cancer 2023; 22:222-230. [PMID: 36944559 DOI: 10.1016/j.clcc.2023.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 01/30/2023] [Accepted: 02/10/2023] [Indexed: 02/25/2023]
Abstract
BACKGROUND The bCTC count is a well-established prognostic biomarker in mCRC, as well as in other tumor types. The aim of this analysis was to evaluate the prognostic/predictive role of the bCTC count (≥3 vs. <3) in previously untreated mCRC. PATIENTS AND METHODS The study involved 589 untreated mCRC patients included in the intention-to-treat population of 2 randomized clinical trials (phase III VISNU-1 [NCT01640405] and phase II VISNU-2 [NCT01640444] studies). RESULTS Of the 589 patients, 349 (59.2%) had bCTC≥3 and 240 (40.7%) had bCTC<3. Multivariate analysis showed that the bCTC count is an independent prognostic factor for overall survival (OS) (HR 0.59, 95% CI 0.48-0.72; P = 0.000) and potential for progression-free survival (PFS) (P = 0.0549). Median OS was 32.9 and 19.5 months in patients with bCTC<3 and bCTC≥3 (P <0.001), respectively. This effect was also observed comparing OS in RASwt patients from both studies. Other prognostic factors were: ECOG-PS, primary tumor site, number of metastatic sites and surgery of the primary tumor. Median OS was lower for patients treated with anti-VEGF versus anti-EGFR (22.3 vs. 33.3 months, P <0.0001) while there were no significant differences in PFS according to the targeted treatment received. CONCLUSION This post-hoc analysis of 2 randomized studies confirms the poor prognosis of patients with bCTC≥3 but this is not associated with other adverse independent prognostic factors such as RAS/BRAF mutations.
Collapse
Affiliation(s)
- P Jiménez-Fonseca
- Department of Medical Oncology. Hospital Universitario Central de Asturias, ISPA, Oviedo, 33011, Spain.
| | - J Sastre
- Department of Medical Oncology. Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, 28040, Spain
| | - P García-Alfonso
- Department of Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, 28007, Spain
| | - M A Gómez-España
- Department of Medical Oncology. Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, 14004, Spain
| | - A Salud
- Department of Medical Oncology, Hospital Universitario Arnau de Vilanova, Lérida, 25198, Spain
| | - S Gil
- Department of Medical Oncology. Hospital Universitario Regional y Virgen de la Victoria, IBIMA, Málaga, 29010, Spain
| | - F Rivera
- Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, 39008, Spain
| | - J J Reina
- Department of Medical Oncology, Complejo Hospitalario Virgen de la Macarena, Sevilla, 41009, Spain
| | - G Quintero
- Department of Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, 27003, Spain
| | - M Valladares-Ayerbes
- Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain
| | - M J Safont
- Department of Medical Oncology, Hospital General Universitario de Valencia, CIBERONC, Universidad de Valencia, Valencia, 46014, Spain
| | - A La Casta
- Department of Medical Oncology, Hospital de Donostia, Guipúzcoa, 20014, Spain
| | - L Robles-Díaz
- Department of Medical Oncology. Hospital Universitario 12 de Octubre, Madrid, 28041, Spain
| | - B García-Paredes
- Department of Medical Oncology. Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, 28040, Spain
| | - R López López
- Department of Medical Oncology and Translational Medical Oncology Group. Hospital Universitario Santiago de Compostela and Health Research Institute (IDIS), CIBERONC, Santiago de Compostela, 15706, Spain
| | - M Guillot
- Department of Medical Oncology. Hospital Universitario Son Espases, Palma de Mallorca, 07120, Spain
| | - J Gallego
- Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, 03203, Spain
| | - V Alonso-Orduña
- Department of Medical Oncology, Hospital Universitario Miguel Servet. Instituto de Investigación Sanitaria de Aragón (IISA), Zaragoza, 50009, Spain
| | - E Diaz-Rubio
- Department of Medical Oncology. Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, 28040, Spain
| | - E Aranda
- Department of Medical Oncology. Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, 14004, Spain
| | | |
Collapse
|
5
|
Gutierrez E, Carrion I, Olmos C, Jimenez P, Nombela L, Pozo E, Mahia P, Gil S, De Agustin A, Islas F. Cardiac damage staging in patients undergoing TAVR. Incremental value of global longitudinal strain and right ventricular-arterial coupling. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Transcatheter aortic valve replacement (TAVR) is nowadays a safe and increasingly frequent option to treat severe aortic stenosis (AS). Cardiac damage staging has been proposed and validated in some studies as a prognostic tool; however, many patients continue to undergo aortic valve replacement only after there is evidence of cardiac damage. The aim of this study is to assess the potential incremental value of global longitudinal strain (GLS) and right ventricular-arterial coupling (RV-VAc) in the prognostic performance of the cardiac damage staging.
Methods
Consecutive patients with AS and undergoing TAVR were included in our hospital registry. Baseline echocardiography was performed before TAVR according to current guidelines. For this study, patients were classified based on the following stage of cardiac damage: Stage 0: no cardiac damage; Stage 1: left ventricular (LV) damage (LV ejection fraction (LVEF) <50%, LV mass index >95 g/m2 for women, >115 g/m2 for men); Stage 2: left atrial (LA) or mitral valve damage (LA volume index >34 ml/m2, mitral regurgitation moderate-severe, or presence of atrial fibrillation); Stage 3: pulmonary vasculature or tricuspid valve damage (systolic pulmonary artery pressure 60 mmHg, or tricuspid regurgitation moderate-severe); Stage 4: RV damage (TAPSE <1.7 cm, S' <9.5 cm/s).
Results
496 patients were studied. Mean age of the cohort was 81.9±6.2 years, mean aortic valve area was 0.86±0.6 cm2, mean LVEF was 57.9±12.3%, mean LV-GLS was −15.6±3.5% and RV-Vac was 0.61±0.34. Table 1 shows clinical and echo characteristics of patients. Only one patient (0.2%) met criteria for stage 0; 38 (7.7%) patients were in stage 1; 159 (32.1%) patients in stage 2, 157 (31.7%) patients in stage 3 and 141 (28.4%) patients in stage 4. 1-year mortality for stage 1 was (10.5%), for stage 2 (13.7%), for stage 3 (32.2%) and for stage 4 (19.5%). The area under the ROC curve (AUC) for 1-year mortality for the cardiac damage staging system was 0.622, CI (0.539–0.705); the best cut-off value for LV-GLS to predict 1-year mortality was −14% with an AUC of 0.634 CI (0.487–0.781) and RV-VAc had an AUC of 0.748 CI (0.638–858). Finally, the model that included the staging system, LV-GLS and RV-VAc had an AUC ROC of 0.875, CI (0.780–0.971) (Figure 1).
Conclusions
Cardiac damage staging is a good prognostic tool and it has been validated in several studies, however, the addition of feasible and widely available echo parameters such as LV-GLS and RV-VAc can significantly increase its prognostic yield.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- E Gutierrez
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - I Carrion
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - C Olmos
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - P Jimenez
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - L Nombela
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - E Pozo
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - P Mahia
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - S Gil
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - A De Agustin
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| | - F Islas
- Hospital Clinic San Carlos, Cardiovascular Institute , Madrid , Spain
| |
Collapse
|
6
|
Alcazar M, Escribano J, Ferré N, Closa-Monasterolo R, Selma-Royo M, Feliu A, Castillejo G, Luque V, Closa-Monasterolo R, Escribano J, Luque V, Feliu-Rovira A, Ferré N, Muñoz-Hernando J, Gutiérrez-Marín D, Zaragoza-Jordana M, Gispert-Llauradó M, Rubio-Torrents M, Núñez-Roig M, Alcázar M, Sentís S, Esteve M, Monné-Gelonch R, Basora J, Flores G, Hsu P, Rey-Reñones C, Alegret C, Guillen N, Alegret-Basora C, Ferre R, Arasa F, Alejos A, Diéguez M, Serrano M, Mallafré M, González-Hidalgo R, Braviz L, Resa A, Palacios M, Sabaté A, Simón L, Losilla A, De La Torre S, Rosell L, Adell N, Pérez C, Tudela-Valls C, Caro-Garduño R, Salvadó O, Pedraza A, Conchillo J, Morillo S, Garcia S, Mur E, Paixà S, Tolós S, Martín R, Aguado F, Cabedo J, Quezada L, Domingo M, Ortega M, Garcia R, Romero O, Pérez M, Fernández M, Villalobos M, Ricomà G, Capell E, Bosch M, Donado A, Sanchis F, Boix A, Goñi X, Castilla E, Pinedo M, Supersaxco L, Ferré M, Contreras J, Sanz-Manrique N, Lara A, Rodríguez M, Pineda T, Segura S, Vidal S, Salvat M, Mimbrero G, Albareda A, Guardia J, Gil S, Lopez M, Ruiz-Escusol S, Gallardo S, Machado P, Bocanegra R, Espejo T, Vendrell M, Solé C, Urbano R, Vázquez M, Fernández-Antuña L, Barrio M, Baudoin A, González N, Olivé R, Lara R, Dinu C, Vidal C, González S, Ruiz-Morcillo E, Ainsa M, Vilalta P, Aranda B, Boada A, Balcells E. Gut microbiota is associated with metabolic health in children with obesity. Clin Nutr 2022; 41:1680-1688. [DOI: 10.1016/j.clnu.2022.06.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 03/16/2022] [Accepted: 06/04/2022] [Indexed: 11/03/2022]
|
7
|
Goutaudier N, Martinelli N, Chevalère J, Dezecache G, Belletier C, Huguet P, Droit-Volet S, Gil S. Affective experiences during COVID-19 pandemic lockdown and posttraumatic growth: A 1-year longitudinal study in France. J Affect Disord 2022; 310:472-476. [PMID: 35577154 PMCID: PMC9101774 DOI: 10.1016/j.jad.2022.05.056] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Revised: 02/18/2022] [Accepted: 05/10/2022] [Indexed: 12/14/2022]
Abstract
BACKGROUND The COVID-19 crisis has resulted in major restrictions on daily life that are undeniably detrimental to individual wellbeing. Nevertheless, there may be positive psychological changes over the longer term, particularly in the form of posttraumatic growth (PTG). METHODS A total of 1075 individuals representative of the French population took part in an online survey during the first lockdown (T1: March to May 2020) and 1 year later (T2). Their affective experiences at T1 were analyzed, together with the development of PTG at T2. RESULTS Three affective profiles were identified at T1: one associated with feelings of loneliness and depressive symptoms (Loneliness cluster), one with positive feelings (Happiness cluster), and one with rather negative feelings of anger and fear, but also a feeling of happiness (Negative-moderate cluster). PTG was generally low at T2, with the Negative-moderate cluster achieving the highest score. LIMITATIONS This study was based on an online survey, and an exploratory cluster analysis was conducted. Complementary studies should be conducted to determine the predictive value of our findings. CONCLUSIONS Within the space of 1 year following the first lockdown due to COVID-19, people living in France, especially those who had experienced a mixture of feelings during lockdown, appeared to develop some form of PTG. Nevertheless, PTG was rather weak overall.
Collapse
Affiliation(s)
- N. Goutaudier
- Université de Poitiers; CNRS (CeRCA UMR7295), France,Corresponding author at: Centre de Recherches sur la Cognition et l'Apprentissage (CeRCA), Bât. A5, MSHS, 5 rue Théodore Lefebvre, TSA 21103, 86073 Poitiers Cedex 9, France
| | - N. Martinelli
- Université Clermont Auvergne; CNRS, LAPSCO, F-63000 Clermont-Ferrand, France
| | - J. Chevalère
- Université Clermont Auvergne; CNRS, LAPSCO, F-63000 Clermont-Ferrand, France
| | - G. Dezecache
- Université Clermont Auvergne; CNRS, LAPSCO, F-63000 Clermont-Ferrand, France
| | - C. Belletier
- Université Clermont Auvergne; CNRS, LAPSCO, F-63000 Clermont-Ferrand, France
| | - P. Huguet
- Université Clermont Auvergne; CNRS, LAPSCO, F-63000 Clermont-Ferrand, France
| | - S. Droit-Volet
- Université Clermont Auvergne; CNRS, LAPSCO, F-63000 Clermont-Ferrand, France
| | - S. Gil
- Université de Poitiers; CNRS (CeRCA UMR7295), France
| |
Collapse
|
8
|
Suárez-Vázquez S, Moreno-Román E, Zanella R, Cruz-López A, García-Goméz C, Nieto-Márquez A, Gil S. Insight into the surface reaction mechanism of toluene oxidation over a composite CeOx/La1-xCexMnO3 catalyst using Drifts. Chem Eng Sci 2022. [DOI: 10.1016/j.ces.2022.117831] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Schneider H, Albrecht C, Ahmed MS, Broekhuizen M, Aengenheister L, Buerki-Thurnherr T, Danser AJ, Gil S, Hansson SR, Greupink R, Lewis RM, Markert UR, Mathiesen L, Powles-Glover N, Wadsack C, Brownbill P. Ex vivo dual perfusion of an isolated human placenta cotyledon: Towards protocol standardization and improved inter-centre comparability. Placenta 2022; 126:83-89. [DOI: 10.1016/j.placenta.2022.05.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 04/06/2022] [Accepted: 05/04/2022] [Indexed: 12/29/2022]
|
10
|
Servent D, Malgorn C, Bernes M, Gil S, Simasotchi C, Hérard AS, Delzescaux T, Thai R, Barbe P, Keck M, Beau F, Zakarian A, Dive V, Molgó J. First evidence that emerging pinnatoxin-G, a contaminant of shellfish, reaches the brain and crosses the placental barrier. Sci Total Environ 2021; 790:148125. [PMID: 34380275 DOI: 10.1016/j.scitotenv.2021.148125] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 04/27/2021] [Accepted: 05/26/2021] [Indexed: 06/13/2023]
Abstract
Massive proliferation of some toxic marine dinoflagellates is responsible for the occurrence of harmful algal blooms and the contamination of fish and shellfish worldwide. Pinnatoxins (PnTx) (A-H) comprise an emerging phycotoxin family belonging to the cyclic imine toxin group. Interest has been focused on these lipophilic, fast-acting and highly potent toxins because they are widely found in contaminated shellfish, and can represent a risk for seafood consumers. PnTx display a potent antagonist effect on nicotinic acetylcholine receptors (nAChR), and in this study we assessed in vivo the ability of PnTx-G to cross physiological barriers to reach its molecular target. Radiolabeled [3H]-PnTx-G synthesized with good radiochemical purity and yield retained the high affinity of the natural toxin. Oral gavage or intravenous administration to adult rats and digital autoradiographic analyses revealed the biodistribution and toxicokinetics of [3H]-PnTx-G, which is rapidly cleared from blood, and accumulates in the liver and small intestine. The labeling of peripheral and brain adult/embryo rat tissues highlights its ability to cross the intestinal, blood-brain and placental barriers. High-resolution 3D-imaging and in vitro competition studies on rat embryo sections revealed the specificity of [3H]-PnTx-G binding and its selectivity for muscle and neuronal nAChR subtypes (such as α7 subtype). The use of a human perfused cotyledon model and mass spectrometry analyses disclosed that PnTx-G crosses the human placental barrier. The increasing worldwide occurrence of both the dinoflagellate Vulcanodinium rugosum and PnTx-contaminated shellfish, due to climate warming, raises concerns about the potential adverse impact that exposure to pinnatoxins may have for human health.
Collapse
Affiliation(s)
- Denis Servent
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, ERL CNRS 9004, F-91191 Gif sur Yvette, France.
| | - Carole Malgorn
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, ERL CNRS 9004, F-91191 Gif sur Yvette, France
| | - Mylène Bernes
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, ERL CNRS 9004, F-91191 Gif sur Yvette, France
| | - Sophie Gil
- Université de Paris, UMR-S1139, Faculté de Pharmacie de Paris, France
| | | | - Anne-Sophie Hérard
- Université Paris-Saclay, UMR9199, CNRS, CEA, MIRCen, Fontenay-aux-Roses, France
| | - Thierry Delzescaux
- Université Paris-Saclay, UMR9199, CNRS, CEA, MIRCen, Fontenay-aux-Roses, France
| | - Robert Thai
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, ERL CNRS 9004, F-91191 Gif sur Yvette, France
| | - Peggy Barbe
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, ERL CNRS 9004, F-91191 Gif sur Yvette, France
| | - Mathilde Keck
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, ERL CNRS 9004, F-91191 Gif sur Yvette, France
| | - Fabrice Beau
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, ERL CNRS 9004, F-91191 Gif sur Yvette, France
| | - Armen Zakarian
- University of California, Santa Barbara, Department of Chemistry and Biochemistry, CA 93106-9510, USA
| | - Vincent Dive
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, ERL CNRS 9004, F-91191 Gif sur Yvette, France
| | - Jordi Molgó
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, ERL CNRS 9004, F-91191 Gif sur Yvette, France.
| |
Collapse
|
11
|
Simasotchi C, Chissey A, Jungers G, Fournier T, Seralini GE, Gil S. A Glyphosate-Based Formulation but Not Glyphosate Alone Alters Human Placental Integrity. Toxics 2021; 9:220. [PMID: 34564371 PMCID: PMC8472883 DOI: 10.3390/toxics9090220] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Revised: 09/02/2021] [Accepted: 09/09/2021] [Indexed: 12/27/2022]
Abstract
Glyphosate (G)-based herbicidal formulations, such as the most commonly used one, Roundup (R), are major pesticides used worldwide on food and feed. Pregnant women may be frequently exposed to R compounds. These are composed of G, which is declared as the active principle, and other products contained in formulations, named formulants, which have been declared as inerts and diluents by the manufacturers. These formulants have, in fact, been demonstrated to be much more toxic than G, in particular to placental and embryonic human cells. In this work, we thus compared the effect of G and a GT+ formulation named R, using placental perfusion ex vivo. R, but not G alone, was demonstrated to alter the placental permeability of a known small model molecule, antipyrine. Similar results were observed for the fetal venous flow rate. The transfer of G alone increases with time, but is significantly decreased in presence of its formulants. The perfusion of R provokes a destruction of fetal vessels, as demonstrated by immunohistochemistry. Formulants obviously alter the fetal-placental circulation and placental integrity according to time of exposure. Therefore, G does not appear to be the main toxic agent of R. Formulants, although undeclared, include polyoxyethanolamines, PAHs, or heavy metals, and may be responsible for this toxicity. These compounds are also present in other pesticides. The progressive blood flow reduction due to the toxic compounds of formulations may diminish the nutrient supply to the fetus, alter the development, and may enhance the poisoning effects. Although these are preliminary results, they could at least partially explain some adverse pregnancy outcomes in mothers exposed to pesticides or other environmental pollutants. The debate on glyphosate alone is proven insufficient for the understanding of the toxicity.
Collapse
Affiliation(s)
- Christelle Simasotchi
- Faculté de Pharmacie, Université de Paris, INSERM, U1139, 3PHM, 4 Avenue de l’Observatoire, F-75006 Paris, France; (C.S.); (A.C.); (T.F.); (S.G.)
| | - Audrey Chissey
- Faculté de Pharmacie, Université de Paris, INSERM, U1139, 3PHM, 4 Avenue de l’Observatoire, F-75006 Paris, France; (C.S.); (A.C.); (T.F.); (S.G.)
| | - Gérald Jungers
- Network on Risks, Quality and Sustainable Development, MRSH, Faculty of Sciences, University of Caen Normandy, Esplanade de la Paix, F-14032 Caen, France;
| | - Thierry Fournier
- Faculté de Pharmacie, Université de Paris, INSERM, U1139, 3PHM, 4 Avenue de l’Observatoire, F-75006 Paris, France; (C.S.); (A.C.); (T.F.); (S.G.)
| | - Gilles-Eric Seralini
- Network on Risks, Quality and Sustainable Development, MRSH, Faculty of Sciences, University of Caen Normandy, Esplanade de la Paix, F-14032 Caen, France;
| | - Sophie Gil
- Faculté de Pharmacie, Université de Paris, INSERM, U1139, 3PHM, 4 Avenue de l’Observatoire, F-75006 Paris, France; (C.S.); (A.C.); (T.F.); (S.G.)
| |
Collapse
|
12
|
Benavides M, Alcaide-Garcia J, Torres E, Gil S, Durán G, Reyna C, Wolman R, Alvarez M, Kushnir M, Faull I, Muñoz M, Alba E. 503P Mutational landscape in synchronous unresectable metastatic colorectal cancer (mCRC) according to upfront primary tumour resection (UPTR). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
13
|
Valladares-Ayerbes M, Toledano Fonseca M, Vieitez de Prado J, Inga-Saavedra E, Gil S, Graña Suarez B, García-Paredes B, Salud A, Rivera Herrero F, Salgado Fernandez M, García-Alfonso P, López-López R, Ferreiro Monteagudo R, Sastre J, Diaz-Rubio E, Aranda E. P-99 Circulating RNA detection, circulating tumor cells count, and molecular tumor profiling in a cohort of untreated metastatic colorectal cancer: A prospective multicenter ancillary study to the randomized VISNÚ trials. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
14
|
Verdial C, Carneiro C, Machado I, Tavares L, Almeida V, Oliveira M, Gil S. Controlling bacteriological contamination of environmental surfaces at the biological isolation and containment unit of a veterinary teaching hospital. Ir Vet J 2021; 74:18. [PMID: 34183065 PMCID: PMC8240409 DOI: 10.1186/s13620-021-00197-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Accepted: 06/15/2021] [Indexed: 11/23/2022] Open
Abstract
Background The Biological Isolation and Containment Unit (BICU) is a subunit of the Teaching Hospital of the Faculty of Veterinary Medicine of the University of Lisbon, Portugal, for the admission of animals with confirmed infectious diseases or under clinical suspicion and waiting for a diagnosis. As a high-risk environment for the transmission of infectious agents, it is extremely important to implement programs for the surveillance of nosocomial microorganisms in these facilities. The purpose of this study was to evaluate the level of bacterial contamination of the BICU environmental surfaces and to implement corrective actions on disinfection protocols. Swab samples were collected from selected environmental surfaces in 3 different areas of the BICU (isolation, work, and preparatory rooms) to evaluate the total aerobic bacterial load and investigate the presence of 4 nosocomial microorganisms: vancomycin-resistant Enterococcus spp., methicillin-resistant Staphylococcus aureus, 3rd-generation cephalosporin-resistant Escherichia coli, and carbapenem-resistant Pseudomonas aeruginosa. Bacterial quantification was performed by using non-selective media, while specific selective media were used for the isolation of the target microorganisms. Isolates were identified based on their macro and microscopic characteristics and their biochemical profile. Subsequently, new disinfection protocols were implemented, and their effectiveness evaluated. Results The surfaces with the highest bacterial load in the isolation, preparatory, and worker’s rooms were the cages, hand-held sponge, and telephone, respectively. Regarding the 4 pathogens investigated, Enterococcus spp. were the most frequently isolated (11.3%), followed by E. coli (1.5%) and P. aeruginosa (1.5%). One of the P. aeruginosa isolates obtained was resistant to imipenem. In the end, new disinfection protocols were implemented, which proved to be effective in reducing bacterial counts by 99.99% in cages and the sponge, and by 90 to 99% on the telephone. Conclusions This study allows to conclude that the cages and the human contact surfaces were the most contaminated in the isolation rooms. Nevertheless, the new disinfection strategies seemed to be effective in reducing environmental contamination, including by some potentially nosocomial agents, although more samples must be analyzed for definitive conclusions. These results may contribute to highlight the importance of infection prevention and control measures, as fundamental tools to reduce the spread of infectious agents in the hospital environment.
Collapse
Affiliation(s)
- C Verdial
- Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal
| | - C Carneiro
- Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal.,CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal
| | - I Machado
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal.,Veterinary Teaching Hospital, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal
| | - L Tavares
- Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal.,CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal
| | - V Almeida
- Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal.,CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal
| | - M Oliveira
- Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal.,CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal
| | - S Gil
- Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal. .,CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal. .,Veterinary Teaching Hospital, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477, Lisbon, Portugal.
| |
Collapse
|
15
|
Liu F, Simasotchi C, Vibert F, Zhu W, Gil S, Degrelle SA, Fournier T. Age and Sex-Related Changes in Human First-Trimester Placenta Transcriptome and Insights into Adaptative Responses to Increased Oxygen. Int J Mol Sci 2021; 22:ijms22062901. [PMID: 33809345 PMCID: PMC8001632 DOI: 10.3390/ijms22062901] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2021] [Revised: 03/09/2021] [Accepted: 03/10/2021] [Indexed: 12/17/2022] Open
Abstract
Physiological oxygen tension rises dramatically in the placenta between 8 and 14 weeks of gestation. Abnormalities in this period can lead to gestational diseases, whose underlying mechanisms remain unclear. We explored the changes at mRNA level by comparing the transcriptomes of human placentas at 8–10 gestational weeks and 12–14 gestational weeks. A total of 20 samples were collected and divided equally into four groups based on sex and age. Cytotrophoblasts were isolated and sequenced using RNAseq. Key genes were identified using two different methods: DESeq2 and weighted gene co-expression network analysis (WGCNA). We also constructed a local database of known targets of hypoxia-inducible factor (HIF) subunits, alpha and beta, to investigate expression patterns likely linked with changes in oxygen. Patterns of gene enrichment in and among the four groups were analyzed based on annotations of gene ontology (GO) and KEGG pathways. We characterized the similarities and differences between the enrichment patterns revealed by the two methods and the two conditions (age and sex), as well as those associated with HIF targets. Our results provide a broad perspective of the processes that are active in cytotrophoblasts during the rise in physiological oxygen, which should benefit efforts to discover possible drug-targeted genes or pathways in the human placenta.
Collapse
Affiliation(s)
- Fulin Liu
- Pathophysiology & Pharmacotoxicology of the Human Placenta, Pre & Postnatal Microbiota, Université de Paris, INSERM, 3PHM, F-75006 Paris, France; (F.L.); (C.S.); (F.V.); (S.G.); (S.A.D.)
| | - Christelle Simasotchi
- Pathophysiology & Pharmacotoxicology of the Human Placenta, Pre & Postnatal Microbiota, Université de Paris, INSERM, 3PHM, F-75006 Paris, France; (F.L.); (C.S.); (F.V.); (S.G.); (S.A.D.)
- Fondation PremUp, F-75006 Paris, France
| | - Françoise Vibert
- Pathophysiology & Pharmacotoxicology of the Human Placenta, Pre & Postnatal Microbiota, Université de Paris, INSERM, 3PHM, F-75006 Paris, France; (F.L.); (C.S.); (F.V.); (S.G.); (S.A.D.)
| | - Wencan Zhu
- UMR Applied Mathematics & Informatics, AgroParisTech-Université Paris-Saclay, F-75005 Paris, France;
| | - Sophie Gil
- Pathophysiology & Pharmacotoxicology of the Human Placenta, Pre & Postnatal Microbiota, Université de Paris, INSERM, 3PHM, F-75006 Paris, France; (F.L.); (C.S.); (F.V.); (S.G.); (S.A.D.)
- Fondation PremUp, F-75006 Paris, France
| | - Séverine A. Degrelle
- Pathophysiology & Pharmacotoxicology of the Human Placenta, Pre & Postnatal Microbiota, Université de Paris, INSERM, 3PHM, F-75006 Paris, France; (F.L.); (C.S.); (F.V.); (S.G.); (S.A.D.)
- Inovarion, F-75005 Paris, France
| | - Thierry Fournier
- Pathophysiology & Pharmacotoxicology of the Human Placenta, Pre & Postnatal Microbiota, Université de Paris, INSERM, 3PHM, F-75006 Paris, France; (F.L.); (C.S.); (F.V.); (S.G.); (S.A.D.)
- Correspondence:
| |
Collapse
|
16
|
Sastre J, García-Alfonso P, Viéitez JM, Cano MT, Rivera F, Reina-Zoilo JJ, Salud-Salvia A, Quintero G, Robles-Díaz L, Safont MJ, La Casta A, Gil S, Polo E, Asensio-Martínez E, García-Paredes B, López RL, Guillot M, Valladares-Ayerbes M, Aranda E, Díaz-Rubio E. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study. ESMO Open 2021; 6:100062. [PMID: 33711671 PMCID: PMC7970062 DOI: 10.1016/j.esmoop.2021.100062] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 12/23/2020] [Accepted: 01/15/2021] [Indexed: 01/09/2023] Open
Abstract
Background We explored the influence of BRAF and PIK3CA mutational status on the efficacy of bevacizumab or cetuximab plus 5-fluorouracil/leucovorin and irinotecan (FOLFIRI) as first-line therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). Patients and methods VISNÚ-2 was a multicentre, randomised, phase II study. Patients with RAS wild-type mCRC and <3 circulating tumour cells/7.5 ml blood were stratified by BRAF/PIK3CA status (wild-type versus mutated) and number of affected organs (1 versus >1), and allocated to bevacizumab (5 mg/kg every 2 weeks) or cetuximab (400 mg/m2 then 250 mg/m2 weekly) plus FOLFIRI [irinotecan 180 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 (bolus) then 2400 mg/m2 (46-h continuous infusion) every 2 weeks]. The primary endpoint was progression-free survival (PFS). All analyses were exploratory. Results Two hundred and forty patients with BRAF/PIK3CA wild-type (n = 196) or BRAF- and/or PIK3CA-mutated tumours (n = 44) were enrolled. Median PFS was 12.7 and 8.8 months in patients with BRAF/PIK3CA wild-type and BRAF/PIK3CA-mutated tumours, respectively [hazard ratio (HR) = 1.22; 95% confidence interval (CI) 0.80-1.85; P = 0.3602]. In the BRAF- and/or PIK3CA-mutated cohort, median PFS was 2.8, 8.8 and 15.0 months in patients with BRAF/PI3KCA-mutated (n = 8), BRAF-mutated/PI3KCA wild-type (n = 16) and BRAF wild-type/PI3KCA-mutated (n = 20) tumours, respectively (P = 0.0002). PFS was similar with bevacizumab plus FOLFIRI versus cetuximab plus FOLFIRI in BRAF/PIK3CA wild-type (HR = 0.99; 95% CI 0.67-1.45; P = 0.9486) and BRAF/PIK3CA-mutated tumours (HR = 1.11; 95% CI 0.53-2.35; P = 0.7820). The most common grade 3/4 treatment-related adverse events were neutropenia, diarrhoea and asthenia in both treatment groups. Conclusions BRAF/PIK3CA status influences outcomes in patients with RAS wild-type mCRC but does not appear to assist with the selection of first-line targeted therapy. This study examined if BRAF/PIK3CA mutational status can guide therapy in RAS wild-type mCRC. BRAF mutations were associated with poorer survival outcomes, and were potentiated by PI3KCA mutations. Bevacizumab-FOLFIRI versus cetuximab-FOLFIRI had similar outcomes in BRAF /PIK3CA wild-type and BRAF /PIK3CA-mutated tumours. BRAF and PI3KCA mutations have a role as prognostic but not predictive factors.
Collapse
Affiliation(s)
- J Sastre
- Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.
| | - P García-Alfonso
- Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - J M Viéitez
- Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - M T Cano
- Medical Oncology, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Cordoba, Spain
| | - F Rivera
- Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - J J Reina-Zoilo
- Medical Oncology, Complejo Hospitalario Virgen de la Macarena, Seville, Spain
| | - A Salud-Salvia
- Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain
| | - G Quintero
- Medical Oncology, Hospital Lucus Augusti, Lugo, Spain
| | - L Robles-Díaz
- Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
| | - M J Safont
- Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain
| | - A La Casta
- Medical Oncology, Hospital de Donostia, Guipúzcoa, Spain
| | - S Gil
- Medical Oncology, Hospital Universitario Regional y Virgen de la Victoria, Malaga, Spain
| | - E Polo
- Medical Oncology, Hospital Miguel Servet, Zaragoza, Spain
| | - E Asensio-Martínez
- Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain
| | - B García-Paredes
- Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - R L López
- Medical Oncology, University Clinical Hospital and Health Research Institute (IDIS), CIBERONC, Santiago de Compostela University School of Medicine, Santiago de Compostela, Spain
| | - M Guillot
- Medical Oncology, Hospital Son Espases, Palma de Mallorca, Spain
| | - M Valladares-Ayerbes
- Medical Oncology, Complejo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica (INIBIC), A Coruña, Spain
| | - E Aranda
- Medical Oncology, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Cordoba, Spain
| | - E Díaz-Rubio
- Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | | |
Collapse
|
17
|
Affiliation(s)
- Amandine Weill
- Service de Dermatologie, Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France
- Groupe de recherche Dynamyc, EA7380, Faculté de Santé de Créteil, École nationale vétérinaire d’Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France
- Fondation PremUp, Paris, France
- * E-mail: (AW); (CB)
| | - Charlotte Bernigaud
- Service de Dermatologie, Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France
- Groupe de recherche Dynamyc, EA7380, Faculté de Santé de Créteil, École nationale vétérinaire d’Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France
- * E-mail: (AW); (CB)
| | - Mourad Mokni
- Service de Dermatologie, Hôpital La Rabta, Faculté de Médecine, Université al Manar 2, Laboratoire de Recherche Infection et Santé Publique LR18SP01, Tunis, Tunisie
| | - Sophie Gil
- Fondation PremUp, Paris, France
- Université de Paris, INSERM, UMR-S 1139, 3PHM, Paris, France
| | - Elisabeth Elefant
- Centre de Référence sur les Agents Tératogènes (CRAT), Hôpital Armand Trousseau, AP-HP, Sorbonne Université, Paris, France
| | - Olivier Chosidow
- Service de Dermatologie, Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France
- Groupe de recherche Dynamyc, EA7380, Faculté de Santé de Créteil, École nationale vétérinaire d’Alfort, USC ANSES, Université Paris-Est Créteil, Créteil, France
| |
Collapse
|
18
|
Kisteneff A, Gil S, O'Connell K, Edwards J, Lo B, Derber C. 335 HIV Post Exposure Prophylaxis in the Emergency Department: Barriers and Missed Opportunities. Ann Emerg Med 2020. [DOI: 10.1016/j.annemergmed.2020.09.350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
Cordier AG, Bouvier AS, Vibert F, Martinovic J, Couturier-Tarrade A, Lai-Kuen R, Curis E, Fournier T, Benachi A, Peoc'H K, Gil S. Preserved efficiency of sickle cell disease placentas despite altered morphology and function. Placenta 2020; 100:81-88. [PMID: 32871493 DOI: 10.1016/j.placenta.2020.08.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 08/05/2020] [Accepted: 08/07/2020] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Pregnant women with sickle cell disease (SCD) are at high risk for sickle cell-related complications, obstetrical complications, and perinatal morbidity. Chronic inflammation and the proangiogenic environment associated with SCD have been associated with endothelial damage. It is unknown whether SCD complications could be associated with placental dysfunction or abnormal placental morphology. Moreover, circulating angiogenic factors in pregnant women with SCD are unexplored. METHODS Clinical records, placental and blood samples were collected at term delivery for 21 pregnant patients with SCD and 19 HbAA pregnant controls with adapted to gestational age birth weight newborns. Histological and stereological analyses and scanning electron microscopy (SEM) of the placenta, and PlGF and sFlt1 measurements in blood were performed. RESULTS In the SCD group, the parenchyma-forming villi of placentas were thinner than in controls, and increased fibrinoid necrosis and an overabundance of syncytial knots were seen. SEM revealed elongated intermediate villous endings with a reduction in the number of terminal villi compared to controls, indicating a significant branching defect in SCD placentas. Finally, SCD patients had an imbalance in the angiogenic ratio of sFlt1/PlGF (p = 0.008) with a drop of PlGF concentrations. DISCUSSION We evidence for the first time both abnormal placenta morphology and altered sFlt1/PlGF ratio in SCD patients, uncorrelated with maintained placental efficiency and fetal growth.
Collapse
Affiliation(s)
- Anne-Gael Cordier
- Assistance Publique-Hôpitaux de Paris, Service de Gynécologie Obstétrique, Centre hospitalier universitaire Antoine Béclère, Université Paris-Sud, 92140, Clamart, France; Université de Paris, INSERM UMR-S1139 (3PHM), Sorbonne Paris Cité, Paris, F-75006, France; PremUp Foundation, Paris, F-75014, France; Centre de référence maladies rares. Syndromes drépanocytaires majeurs, thalassémies et autres pathologies rares du globule rouge et de l'érythropoïèse, Paris, France.
| | - Anne-Sophie Bouvier
- Université de Paris, INSERM UMR-S1139 (3PHM), Sorbonne Paris Cité, Paris, F-75006, France; PremUp Foundation, Paris, F-75014, France
| | - Francoise Vibert
- Université de Paris, INSERM UMR-S1139 (3PHM), Sorbonne Paris Cité, Paris, F-75006, France; PremUp Foundation, Paris, F-75014, France
| | - Jelena Martinovic
- Assistance Publique-Hôpitaux de Paris, Service de Fœtopathologie, Centre hospitalier universitaire Antoine Béclère, Université Paris-Sud, Clamart, France; INSERM, UMR, 1195, Université Paris Sud, Paris Saclay, France
| | | | - René Lai-Kuen
- Plateau technique Imagerie Cellulaire et Moléculaire (ICM), UMS, 3612, CNRS, US25 INSERM, Faculté de Pharmacie de Paris, Université Paris Descartes, Sorbonne Paris Cité, France
| | - Emmanuel Curis
- Service de biostatistiques et informatique médicale, Hôpital Saint-Louis, APHP, Paris, France; Laboratoire de biomathématiques, Faculté de pharmacie, Université Paris Descartes, France
| | - Thierry Fournier
- Université de Paris, INSERM UMR-S1139 (3PHM), Sorbonne Paris Cité, Paris, F-75006, France
| | - Alexandra Benachi
- Assistance Publique-Hôpitaux de Paris, Service de Gynécologie Obstétrique, Centre hospitalier universitaire Antoine Béclère, Université Paris-Sud, 92140, Clamart, France; Centre de référence maladies rares. Syndromes drépanocytaires majeurs, thalassémies et autres pathologies rares du globule rouge et de l'érythropoïèse, Paris, France
| | - Katell Peoc'H
- Université de Paris, INSERM UMR-S1139 (3PHM), Sorbonne Paris Cité, Paris, F-75006, France; Assistance Publique-Hôpitaux de Paris, Laboratoire de Biochimie Clinique, HUPNVS, Hôpital Beaujon, Clichy and Université de Paris, UFR de Médecine Xavier Bichat, Paris, France
| | - Sophie Gil
- Université de Paris, INSERM UMR-S1139 (3PHM), Sorbonne Paris Cité, Paris, F-75006, France; PremUp Foundation, Paris, F-75014, France
| |
Collapse
|
20
|
Nedder M, Boland S, Devineau S, Zerrad-Saadi A, Rogozarski J, Lai-Kuen R, Baya I, Guibourdenche J, Vibert F, Chissey A, Gil S, Coumoul X, Fournier T, Ferecatu I. Uptake of Cerium Dioxide Nanoparticles and Impact on Viability, Differentiation and Functions of Primary Trophoblast Cells from Human Placenta. Nanomaterials (Basel) 2020; 10:nano10071309. [PMID: 32635405 PMCID: PMC7407216 DOI: 10.3390/nano10071309] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Revised: 06/30/2020] [Accepted: 07/02/2020] [Indexed: 02/07/2023]
Abstract
The human placenta is at the interface between maternal and fetal circulations, and is crucial for fetal development. The nanoparticles of cerium dioxide (CeO2 NPs) from air pollution are an unevaluated risk during pregnancy. Assessing the consequences of placenta exposure to CeO2 NPs could contribute to a better understanding of NPs’ effect on the development and functions of the placenta and pregnancy outcome. We used primary villous cytotrophoblasts purified from term human placenta, with a wide range of CeO2 NPs concentrations (0.1–101 μg/cm2) and exposure time (24–72 h), to assess trophoblast uptake, toxicity and impact on trophoblast differentiation and endocrine function. We have shown the capacity of both cytotrophoblasts and syncytiotrophoblasts to internalize CeO2 NPs. CeO2 NPs affected trophoblast metabolic activity in a dose and time dependency, induced caspase activation and a LDH release in the absence of oxidative stress. CeO2 NPs decreased the fusion capacity of cytotrophoblasts to form a syncytiotrophoblast and disturbed secretion of the pregnancy hormones hCG, hPL, PlGF, P4 and E2, in accordance with NPs concentration. This is the first study on the impact of CeO2 NPs using human primary trophoblasts that decrypts their toxicity and impact on placental formation and functions.
Collapse
Affiliation(s)
- Margaux Nedder
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Sonja Boland
- BFA, Université de Paris, UMR 8251, CNRS, F-75013 Paris, France; (S.B.); (S.D.)
| | - Stéphanie Devineau
- BFA, Université de Paris, UMR 8251, CNRS, F-75013 Paris, France; (S.B.); (S.D.)
| | - Amal Zerrad-Saadi
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Jasmina Rogozarski
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - René Lai-Kuen
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMS 025—CNRS UMS 3612, F-75006 Paris, France;
| | - Ibtissem Baya
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Jean Guibourdenche
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
- Assistance Publique—Hôpitaux de Paris, Hôpital Cochin, Service d’hormonologie, F-75014 Paris, France
| | - Francoise Vibert
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Audrey Chissey
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Sophie Gil
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Xavier Coumoul
- Université de Paris, INSERM UMR-S 1124, F-75006 Paris, France;
| | - Thierry Fournier
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Ioana Ferecatu
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
- Correspondence: ; Tel.: +33-1-53-73-96-05; Fax: +33-1-44-07-39-92
| |
Collapse
|
21
|
Alves F, Prata S, Nunes T, Gomes J, Aguiar S, Aires da Silva F, Tavares L, Almeida V, Gil S. Canine parvovirus: a predicting canine model for sepsis. BMC Vet Res 2020; 16:199. [PMID: 32539830 PMCID: PMC7294767 DOI: 10.1186/s12917-020-02417-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 06/08/2020] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Sepsis is a severe condition associated with high prevalence and mortality rates. Parvovirus enteritis is a predisposing factor for sepsis, as it promotes intestinal bacterial translocation and severe immunosuppression. This makes dogs infected by parvovirus a suitable study population as far as sepsis is concerned. The main objective of the present study was to evaluate the differences between two sets of SIRS (Systemic Inflammatory Response Syndrome) criteria in outcome prediction: SIRS 1991 and SIRS 2001. The possibility of stratifying and classifying septic dogs was assessed using a proposed animal adapted PIRO (Predisposition, Infection, Response and Organ dysfunction) scoring system. RESULTS The 72 dogs enrolled in this study were scored for each of the PIRO elements, except for Infection, as all were considered to have the same infection score, and subjected to two sets of SIRS criteria, in order to measure their correlation with the outcome. Concerning SIRS criteria, it was found that the proposed alterations on SIRS 2001 (capillary refill time or mucous membrane colour alteration) were significantly associated with the outcome (OR = 4.09, p < 0.05), contrasting with the 1991 SIRS criteria (p = 0.352) that did not correlate with the outcome. No significant statistical association was found between Predisposition (p = 1), Response (p = 0.1135), Organ dysfunction (p = 0.1135), total PIRO score (p = 0.093) and outcome. To explore the possibility of using the SIRS criteria as a fast decision-making tool, a Fast-and-Frugal tree (FFT) was created with a sensitivity of 92% and a specificity of 29%. CONCLUSION These results suggest that increasing the SIRS criteria specificity may improve their prognostic value and their clinical usefulness. In order to improve the proposed PIRO scoring system outcome prediction ability, more specific criteria should be added, mainly inflammatory and organ dysfunction biomarkers.
Collapse
Affiliation(s)
- F. Alves
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - S. Prata
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- Veterinary Teaching Hospital, Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - T. Nunes
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - J. Gomes
- Veterinary Teaching Hospital, Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - S. Aguiar
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - F. Aires da Silva
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - L. Tavares
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - V. Almeida
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| | - S. Gil
- Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- Veterinary Teaching Hospital, Faculty of Veterinary Medicine, ULisboa, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisboa, Portugal
| |
Collapse
|
22
|
Ruiz Ochoa A, Escudero Argaluza J, Alvarez Rodríguez B, Vasques Rocha M, Stoye C, Pompei Fernández O, Gil S, De Dios JR, Calvo-Alen J. FRI0434 PREDICTIVE FACTORS OF SERIOUS INFECTIONS IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS ON TREATMENT WITH TNF INHIBITORS: REAL LIFE DATA. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Serious infections are one of the most feared adverse events in patients treated with biologics. To this regard data coming from randomized and long-term extension studies may not totally applied to the usual clinical practice due to the different profile of the treated patients. To study the associated factors for serious infections in patients with inflammatory arthritis treated with TNF inhibitorsObjectives:To study the associated factors for serious infections in patients with inflammatory arthritis treated with TNF inhibitorsMethods:All the medical records of the patients with inflammatory arthritis being treated with TNF inhibitors at the beginning of 2016 were retrospectively reviewed. All serious infections suffered for these patients until the end of 2018 were recorded. Serious infections were defined as those which required to admitted at the hospital for intravenous treatment. Potential variables associated with the development of these infections including: demographic and clinical characteristics, concomitant treatments or comorbidity (by Charlson index) were studied. Standard statistical tests for descriptive and univariate analyses were used and a multivariable logistic regression model was built to check independent associations.Results:Overall 334 patients (50.3% women) with a mean age of 56.67 (±12.853) were studied: 140 (41.92%) Rheumatoid arthritis (RA), 55 (16.46%) psoriatic arthritis (PsA) and 138 (41.62%) spondyloarthritis (Sp). Forty-five serious infections were observed in 30 patients, being respiratory (40%) and urinary (8.8%) the most frequent localizations. Only one patient died. By univariate analysis, disease duration, age, concomitan use of glucocorticoids (GC) (but not of synthetic DMARDs), Charlson index and specifically Diabetes Mellitus were associated with infection (p< 0.05). The type of arthritis was not associated and the results in the subset of RA patients were overall similar. In the multivariate analysis the use of GC [OR: 5.31 (1.98.14.26)] and the Charlson index [OR:2.48 (1.70;3.60)] were found to be independently associated to infection.Conclusion:In patients with inflammatory arthritis and treated with TNF inhibitors around a 10% developed any serious infection along three years of follow up. Use of GC and comorbidity emerged as the main risk factors for this complication.Disclosure of Interests:None declared
Collapse
|
23
|
Velasquez JC, Zhao Q, Chan Y, Galindo LCM, Simasotchi C, Wu D, Hou Z, Herod SM, Oberlander TF, Gil S, Fournier T, Burd I, Andrews AM, Bonnin A. Correction to " In Utero Exposure to Citalopram Mitigates Maternal Stress Effects on Fetal Brain Development". ACS Chem Neurosci 2020; 11:484. [PMID: 31912736 DOI: 10.1021/acschemneuro.9b00683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
24
|
Sautreuil C, Laquerrière A, Lecuyer M, Brasse-Lagnel C, Jégou S, Bekri S, Marcorelles P, Gil S, Marret S, Gonzalez BJ. [Fetal alcohol exposure: when placenta would help to the early diagnosis of child brain impairments]. Med Sci (Paris) 2019; 35:859-865. [PMID: 31845877 DOI: 10.1051/medsci/2019167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Alcohol consumption during pregnancy constitutes a major cause of neurodevelopmental and behavioral disabilities. Whereas it is possible for clinicians to establish a perinatal diagnosis of fetal alcohol syndrome, the more severe expression of fetal alcohol spectrum disorder (FASD), most FASD children are late or mis-diagnosed due to a lack of clear morphological and neurodevelopmental abnormalities. Several precious years of care are consequently lost. Recent data revealed a functional placenta-brain axis involved in the control of the fetal brain angiogenesis which is impaired by in utero alcohol exposure. Because in the developing fetal brain a correct angiogenesis is required for a correct neurodevelopment, these preclinical and clinical advances pave the way for a new generation of placental biomarkers for early diagnosis of FASD.
Collapse
Affiliation(s)
- Camille Sautreuil
- Inserm U1245, Équipe 4, Rouen Université, Normandie Université, Rouen, France
| | - Annie Laquerrière
- Inserm U1245, Équipe 4, Rouen Université, Normandie Université, Rouen, France - Service de Pathologie, Hôpital Charles-Nicolle, CHU de Rouen, France
| | - Matthieu Lecuyer
- Inserm U1245, Équipe 4, Rouen Université, Normandie Université, Rouen, France
| | | | - Sylvie Jégou
- Inserm U1245, Équipe 4, Rouen Université, Normandie Université, Rouen, France
| | - Soumeya Bekri
- Inserm U1245, Équipe 4, Rouen Université, Normandie Université, Rouen, France - Service de Biochimie métabolique, Hôpital Charles-Nicolle, CHU de Rouen, France
| | | | - Sophie Gil
- Inserm UMR-S1139, Université Paris Descartes, Sorbonne Paris Cité, Fondation PremUp, Paris, France
| | - Stéphane Marret
- Inserm U1245, Équipe 4, Rouen Université, Normandie Université, Rouen, France - Service de Pédiatrie Néonatale et Réanimation, Neuropédiatrie, Camsp, Hôpital Charles-Nicolle, CHU de Rouen, 37 boulevard Gambetta, 76000 Rouen, France
| | - Bruno J Gonzalez
- Inserm U1245, Équipe 4, Rouen Université, Normandie Université, Rouen, France
| |
Collapse
|
25
|
Alhareth K, Valero L, Mohamed KE, Fliedel L, Roques C, Gil S, Mignet N, Fournier T, Andrieux K. Qualitative and quantitative analysis of the uptake of lipoplexes by villous placenta explants. Int J Pharm 2019; 567:118479. [DOI: 10.1016/j.ijpharm.2019.118479] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 06/26/2019] [Accepted: 06/27/2019] [Indexed: 01/18/2023]
|
26
|
Velasquez JC, Zhao Q, Chan Y, Galindo LC, Simasotchi C, Wu D, Hou Z, Herod SM, Oberlander TF, Gil S, Fournier T, Burd I, Andrews AM, Bonnin A. In Utero Exposure to Citalopram Mitigates Maternal Stress Effects on Fetal Brain Development. ACS Chem Neurosci 2019; 10:3307-3317. [PMID: 31184110 DOI: 10.1021/acschemneuro.9b00180] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Human epidemiological and animal-model studies suggest that separate exposure to stress or serotonin-selective reuptake inhibitor (SSRI) antidepressants during pregnancy increases risks for neurodevelopmental disorders in offspring. Yet, little is known about the combined effects of maternal stress and SSRIs with regard to brain development in utero. We found that the placenta is highly permeable to the commonly prescribed SSRI (±)-citalopram (CIT) in humans and mice, allowing rapid exposure of the fetal brain to this drug. We investigated the effects of maternal chronic unpredictable stress in mice with or without maternal oral administration of CIT from embryonic day (E)8 to E17. We assessed fetal brain development using magnetic resonance imaging and quantified changes in serotonergic, thalamocortical, and cortical development. In utero exposure to maternal stress did not affect overall fetal brain growth. However, serotonin tissue content in the fetal forebrain was increased in association with maternal stress; this increase was reversed by maternal CIT. In utero exposure to stress increased the numbers of deep-layer neurons in specific cortical regions, whereas CIT increased overall cell numbers without changing the proportions of layer-specific neurons to offset the effects of stress on deep-layer cortical development. These findings suggest that stress and SSRI exposure in utero differentially impact serotonin-dependent fetal neurodevelopment such that CIT reverses key effects of maternal gestational stress on offspring brain development.
Collapse
Affiliation(s)
- Juan C. Velasquez
- Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, United States
| | - Qiuying Zhao
- Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, United States
| | - Yen Chan
- Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, United States
| | - Ligia C.M. Galindo
- Department of Anatomy, Federal University of Pernambuco, Recife 50670, Brazil
| | | | - Dan Wu
- Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, Maryland 21287, United States
| | - Zhipeng Hou
- Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, Maryland 21287, United States
| | - Skyla M. Herod
- Department of Biology and Chemistry, Azusa Pacific University, Azusa, California 91702, United States
| | - Tim F. Oberlander
- Department of Pediatrics, University of British Columbia, Vancouver, BC V6H 3 V4, Canada
| | - Sophie Gil
- UMR-S 1139 INSERM/University of Paris Descartes, 75006 Paris, France
- PremUp Foundation, 75014 Paris, France
| | - Thierry Fournier
- UMR-S 1139 INSERM/University of Paris Descartes, 75006 Paris, France
- PremUp Foundation, 75014 Paris, France
| | - Irina Burd
- Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, Maryland 21287, United States
| | - Anne M. Andrews
- Terry and Jane Semel Institute for Neuroscience & Human Behavior, Shirley and Stefan Hatos Center for Neuropharmacology, and Departments of Psychiatry and Biobehavioral Sciences and Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, California 90095, United States
| | - Alexandre Bonnin
- Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, United States
| |
Collapse
|
27
|
Shoaito H, Petit J, Chissey A, Auzeil N, Guibourdenche J, Gil S, Laprévote O, Fournier T, Degrelle SA. The Role of Peroxisome Proliferator–Activated Receptor Gamma (PPARγ) in Mono(2-ethylhexyl) Phthalate (MEHP)-Mediated Cytotrophoblast Differentiation. Environ Health Perspect 2019; 127:27003. [PMID: 30810372 PMCID: PMC6752943 DOI: 10.1289/ehp3730] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
BACKGROUND Phthalates are environmental contaminants commonly used as plasticizers in polyvinyl chloride (PVC) products. Recently, exposure to phthalates has been associated with preterm birth, low birth weight, and pregnancy loss. There is limited information about the possible mechanisms linking maternal phthalate exposure and placental development, but one such mechanism may be mediated by peroxisome proliferator–activated receptor γ (PPARγ). PPARγ belongs to the nuclear receptor superfamily that regulates, in a ligand-dependent manner, the transcription of target genes. Studies of PPARγ-deficient mice have demonstrated its essential role in lipid metabolism and placental development. In the human placenta, PPARγ is expressed in the villous cytotrophoblast (VCT) and is activated during its differentiation into syncytiotrophoblast. OBJECTIVES The goal of this study was to investigate the action of mono(2-ethylhexyl) phthalate (MEHP) on PPARγ activity during in vitro differentiation of VCTs. METHODS We combined immunofluorescence, PPARγ activity/hCG assays, western blotting, and lipidomics analyses to characterize the impacts of physiologically relevant concentrations of MEHP (0.1, 1, and 10 μM) on cultured VCTs isolated from human term placentas. RESULTS Doses of 0.1 and 1 μM MEHP showed significantly lower PPARγ activity and less VCT differentiation in comparison with controls, whereas, surprisingly, a 10 μM dose had the opposite effect. MEHP exposure inhibited hCG production and significantly altered lipid composition. In addition, MEHP had significant effects on the mitogen-activated protein kinase (MAPK) pathway. CONCLUSIONS This study suggests that MEHP has a U-shaped dose–response effect on trophoblast differentiation that is mediated by the PPARγ pathway and acts as an endocrine disruptor in the human placenta. https://doi.org/10.1289/EHP3730.
Collapse
Affiliation(s)
- Hussein Shoaito
- UMR-S1139, Faculté de Pharmacie de Paris, Institut national de la santé et de la recherché médicale (Inserm, National Institute of Health & Medical Research), Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Julia Petit
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- UMR 8638, Faculté de Pharmacie de Paris, Centre national de la recherche scientifique (Cnrs, National Center for Scientific Research), Paris, France
| | - Audrey Chissey
- UMR-S1139, Faculté de Pharmacie de Paris, Institut national de la santé et de la recherché médicale (Inserm, National Institute of Health & Medical Research), Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Nicolas Auzeil
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- UMR 8638, Faculté de Pharmacie de Paris, Centre national de la recherche scientifique (Cnrs, National Center for Scientific Research), Paris, France
| | - Jean Guibourdenche
- UMR-S1139, Faculté de Pharmacie de Paris, Institut national de la santé et de la recherché médicale (Inserm, National Institute of Health & Medical Research), Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- Fondation PremUp, Paris, France
- Department of Biological Endocrinology, CHU Cochin, Assistance publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Sophie Gil
- UMR-S1139, Faculté de Pharmacie de Paris, Institut national de la santé et de la recherché médicale (Inserm, National Institute of Health & Medical Research), Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- Fondation PremUp, Paris, France
| | - Olivier Laprévote
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- UMR 8638, Faculté de Pharmacie de Paris, Centre national de la recherche scientifique (Cnrs, National Center for Scientific Research), Paris, France
- Department of Biochemistry, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
| | - Thierry Fournier
- UMR-S1139, Faculté de Pharmacie de Paris, Institut national de la santé et de la recherché médicale (Inserm, National Institute of Health & Medical Research), Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- Fondation PremUp, Paris, France
| | - Séverine A. Degrelle
- UMR-S1139, Faculté de Pharmacie de Paris, Institut national de la santé et de la recherché médicale (Inserm, National Institute of Health & Medical Research), Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- Fondation PremUp, Paris, France
- Inovarion, Paris, France
| |
Collapse
|
28
|
de Rojas I, Romero J, Rodríguez-Gomez O, Pesini P, Sanabria A, Pérez-Cordon A, Abdelnour C, Hernández I, Rosende-Roca M, Mauleón A, Vargas L, Alegret M, Espinosa A, Ortega G, Gil S, Guitart M, Gailhajanet A, Santos-Santos MA, Moreno-Grau S, Sotolongo-Grau O, Ruiz S, Montrreal L, Martín E, Pelejà E, Lomeña F, Campos F, Vivas A, Gómez-Chiari M, Tejero MA, Giménez J, Pérez-Grijalba V, Marquié GM, Monté-Rubio G, Valero S, Orellana A, Tárraga L, Sarasa M, Ruiz A, Boada M. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI). Alzheimers Res Ther 2018; 10:119. [PMID: 30497535 PMCID: PMC6267075 DOI: 10.1186/s13195-018-0444-1] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2018] [Accepted: 10/29/2018] [Indexed: 01/30/2023]
Abstract
BACKGROUND Peripheral biomarkers that identify individuals at risk of developing Alzheimer's disease (AD) or predicting high amyloid beta (Aβ) brain burden would be highly valuable. To facilitate clinical trials of disease-modifying therapies, plasma concentrations of Aβ species are good candidates for peripheral AD biomarkers, but studies to date have generated conflicting results. METHODS The Fundació ACE Healthy Brain Initiative (FACEHBI) study uses a convenience sample of 200 individuals diagnosed with subjective cognitive decline (SCD) at the Fundació ACE (Barcelona, Spain) who underwent amyloid florbetaben(18F) (FBB) positron emission tomography (PET) brain imaging. Baseline plasma samples from FACEHBI subjects (aged 65.9 ± 7.2 years) were analyzed using the ABtest (Araclon Biotech). This test directly determines the free plasma (FP) and total plasma (TP) levels of Aβ40 and Aβ42 peptides. The association between Aβ40 and Aβ42 plasma levels and FBB-PET global standardized uptake value ratio (SUVR) was determined using correlations and linear regression-based methods. The effect of the APOE genotype on plasma Aβ levels and FBB-PET was also assessed. Finally, various models including different combinations of demographics, genetics, and Aβ plasma levels were constructed using logistic regression and area under the receiver operating characteristic curve (AUROC) analyses to evaluate their ability for discriminating which subjects presented brain amyloidosis. RESULTS FBB-PET global SUVR correlated weakly but significantly with Aβ42/40 plasma ratios. For TP42/40, this observation persisted after controlling for age and APOE ε4 allele carrier status (R2 = 0.193, p = 1.01E-09). The ROC curve demonstrated that plasma Aβ measurements are not superior to APOE and age in combination in predicting brain amyloidosis. It is noteworthy that using a simple preselection tool (the TP42/40 ratio with an empirical cut-off value of 0.08) optimizes the sensitivity and reduces the number of individuals subjected to Aβ FBB-PET scanners to 52.8%. No significant dependency was observed between APOE genotype and plasma Aβ measurements (p value for interaction = 0.105). CONCLUSION Brain and plasma Aβ levels are partially correlated in individuals diagnosed with SCD. Aβ plasma measurements, particularly the TP42/40 ratio, could generate a new recruitment strategy independent of the APOE genotype that would improve identification of SCD subjects with brain amyloidosis and reduce the rate of screening failures in preclinical AD studies. Independent replication of these findings is warranted.
Collapse
Affiliation(s)
- Itziar de Rojas
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | | | - O. Rodríguez-Gomez
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | | | - A. Sanabria
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - A. Pérez-Cordon
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - C. Abdelnour
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - I. Hernández
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - M. Rosende-Roca
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - A. Mauleón
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - L. Vargas
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - M. Alegret
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - A. Espinosa
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - G. Ortega
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - S. Gil
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - M. Guitart
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - A. Gailhajanet
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - M. A. Santos-Santos
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - Sonia Moreno-Grau
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - O. Sotolongo-Grau
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - S. Ruiz
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - L. Montrreal
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - E. Martín
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - E. Pelejà
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - F. Lomeña
- Servei de Medicina Nuclear, Hospital Clínic i Provincial, Barcelona, Spain
| | - F. Campos
- Servei de Medicina Nuclear, Hospital Clínic i Provincial, Barcelona, Spain
| | - A. Vivas
- Departament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain
| | - M. Gómez-Chiari
- Departament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain
| | - M. A. Tejero
- Departament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain
| | - J. Giménez
- Departament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain
| | | | - G. M. Marquié
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - G. Monté-Rubio
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - S. Valero
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - A. Orellana
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - L. Tárraga
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | | | - A. Ruiz
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| | - M. Boada
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, C/ Marquès de Sentmenat, 57, 08029 Barcelona, Spain
| |
Collapse
|
29
|
Berveiller P, Mir O, Degrelle SA, Tsatsaris V, Selleret L, Guibourdenche J, Evain-Brion D, Fournier T, Gil S. Chemotherapy in pregnancy: exploratory study of the effects of paclitaxel on the expression of placental drug transporters. Invest New Drugs 2018; 37:1075-1085. [PMID: 30367323 DOI: 10.1007/s10637-018-0677-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2018] [Accepted: 10/02/2018] [Indexed: 12/19/2022]
Abstract
Introduction The use of paclitaxel in pregnant cancer patients is feasible in terms of fetal safety, but little is known about the effects of paclitaxel on the placenta. Using three experimental models, we aimed to assess the effects of paclitaxel on the expression of placental drug transporters. Methods In the in vitro model (human primary trophoblast culture), trophoblasts were isolated from normal term placentas and subsequently exposed to paclitaxel. The transcriptional regulation of 84 genes encoding for drug transporters, and the protein expression of ABCB1/P-gp and ABCG2/BCRP were assessed. In the in vivo model, placental tissues isolated from pregnant cancer patients treated with paclitaxel were analyzed to assess the protein expression of ABCB1/P-gp and ABCG2/BCRP. The same parameters were assessed in extracts from human placental cotyledons perfused ex vivo with paclitaxel. Results In the in vitro model, the expression of twelve drug-transporters genes was found to be significantly down-regulated after exposure to paclitaxel, including ABCC10, SLC28A3, SLC29A2, and ATP7B (involved in the transport of taxanes, antimetabolites, and cisplatin, respectively). The protein expression of ABCB1/P-gp increased by 1.3-fold after paclitaxel administration. Finally, the protein expression of ABCB1/P-gp and ABCG2/BCRP was higher in cotyledons from mothers treated with multiple doses of paclitaxel during pregnancy than in cotyledons perfused with a single dose of paclitaxel. Discussion Paclitaxel modulates the expression of placental drug transporters involved in the disposition of various anticancer agents. Further studies will be needed to assess the impact of repeated or prolonged exposure to paclitaxel on the expression and function of placental drug transporters.
Collapse
Affiliation(s)
- Paul Berveiller
- INSERM, UMR-S1139, Paris, France.
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
- Department of Gynecology and Obstetrics, Centre Hospitalier Intercommunal de Poissy Saint Germain, 10, rue du champ Gaillard, F78300, Poissy, France.
| | - Olivier Mir
- Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France
| | - Séverine A Degrelle
- INSERM, UMR-S1139, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Vassilis Tsatsaris
- INSERM, UMR-S1139, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- Department of Obstetrics, Port-Royal Maternity, Cochin Teaching Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
- PremUp Foundation, Paris, France
| | - Lise Selleret
- Department of Obstetrics and Gynecology, Tenon Teaching Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Jean Guibourdenche
- Department of Hormonal Biology, Cochin Teaching Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Danièle Evain-Brion
- INSERM, UMR-S1139, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- PremUp Foundation, Paris, France
| | - Thierry Fournier
- INSERM, UMR-S1139, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- PremUp Foundation, Paris, France
| | - Sophie Gil
- INSERM, UMR-S1139, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- PremUp Foundation, Paris, France
| |
Collapse
|
30
|
Nguyen T, Berrada-Gomez MP, Rielland A, Bellec M, Gil S, De Javel D, Ferret PJ. Usage patterns of cosmetic products by pregnant women. Toxicol Lett 2018. [DOI: 10.1016/j.toxlet.2018.06.804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Manceau H, Puy V, Schmitt CM, Gil S, Lefebvre T, Allaf B, Rosenblatt J, Gouya L, Puy H, Muller F, Peoc'h K. Characterization and origin of heme precursors in amniotic fluid: lessons from normal and pathological pregnancies. Pediatr Res 2018; 84:80-84. [PMID: 29795201 DOI: 10.1038/s41390-018-0011-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Revised: 03/21/2018] [Accepted: 03/22/2018] [Indexed: 11/09/2022]
Abstract
BACKGROUND Heme is the prosthetic group of numerous proteins involved in vital processes such as oxygen transport, oxidative stress, and energetic mitochondrial metabolism. Free heme also plays a significant role at early stages of development and in cell differentiation processes. The metabolism of heme by the fetal placenta unit is not well-established in humans. METHODS In a retrospective study, we measured heme precursors in the amniotic fluid (AF) of 51 healthy women, and 10 AF samples from pregnancies with either upper or lower intestinal atresia or ileus were also analyzed. RESULTS We showed that the porphyrin precursors aminolevulinic acid, porphobilinogen, and protoporphyrin IX are present at the limit of detection in the AF. Total porphyrin levels decreased progressively from week 13 to week 33 (p < 0.01). Interestingly, uroporphyrin, initially detected as traces, increased with maturation, in contrast to coproporphyrin. Uro- and coproporphyrins were type I immature isomers (>90%), suggesting a lack of maturity in the fetal compartment of the heme pathway. Finally, the differential analysis of AF from normal and pathological pregnancies demonstrated the predominant hepatic origin of fetal porphyrins excreted in the AF. CONCLUSION This study gives the first insight into heme metabolism in the AF during normal and pathological pregnancies.
Collapse
Affiliation(s)
- Hana Manceau
- Biochimie Clinique, Hôpital Beaujon, APHP, HUPNVS, Clichy, France.,UMRs 1149, Centre de Recherche sur l'Inflammation, Institut National de la Santé et de la Recherche Médicale, F-75018, Paris, France
| | - Vincent Puy
- Reproductive Medicine and Medical Cytogenetics Department, Regional University Hospital and School of Medicine, Amiens, France
| | - Caroline M Schmitt
- UMRs 1149, Centre de Recherche sur l'Inflammation, Institut National de la Santé et de la Recherche Médicale, F-75018, Paris, France.,Centre Français des Porphyries, Hôpital Louis Mourier, APHP, HUPNVS, Colombes, France
| | - Sophie Gil
- UMRs1139, UFR des Sciences Pharmaceutiques, Université Paris Descartes, Paris, France
| | - Thibaud Lefebvre
- UMRs 1149, Centre de Recherche sur l'Inflammation, Institut National de la Santé et de la Recherche Médicale, F-75018, Paris, France.,Centre Français des Porphyries, Hôpital Louis Mourier, APHP, HUPNVS, Colombes, France
| | - Bichr Allaf
- Biochimie-Hormonologie, Hôpital Robert Debré, APHP, Paris, France
| | | | - Laurent Gouya
- UMRs 1149, Centre de Recherche sur l'Inflammation, Institut National de la Santé et de la Recherche Médicale, F-75018, Paris, France.,Centre Français des Porphyries, Hôpital Louis Mourier, APHP, HUPNVS, Colombes, France
| | - Hervé Puy
- UMRs 1149, Centre de Recherche sur l'Inflammation, Institut National de la Santé et de la Recherche Médicale, F-75018, Paris, France.,Centre Français des Porphyries, Hôpital Louis Mourier, APHP, HUPNVS, Colombes, France
| | - Francoise Muller
- Biochimie-Hormonologie, Hôpital Robert Debré, APHP, Paris, France
| | - Katell Peoc'h
- Biochimie Clinique, Hôpital Beaujon, APHP, HUPNVS, Clichy, France. .,UMRs1139, UFR des Sciences Pharmaceutiques, Université Paris Descartes, Paris, France.
| |
Collapse
|
32
|
Petit J, Wakx A, Gil S, Fournier T, Auzeil N, Rat P, Laprévote O. Lipidome-wide disturbances of human placental JEG-3 cells by the presence of MEHP. Biochimie 2018; 149:1-8. [DOI: 10.1016/j.biochi.2018.03.002] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Accepted: 03/05/2018] [Indexed: 01/05/2023]
|
33
|
Valero L, Alhareth K, Gil S, Lecarpentier E, Tsatsaris V, Mignet N, Fournier T, Andrieux K. Nanomedicine as a potential approach to empower the new strategies for the treatment of preeclampsia. Drug Discov Today 2018; 23:1099-1107. [DOI: 10.1016/j.drudis.2018.01.048] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2017] [Revised: 12/28/2017] [Accepted: 01/24/2018] [Indexed: 01/27/2023]
|
34
|
Valero L, Alhareth K, Gil S, Simasotchi C, Roques C, Scherman D, Mignet N, Fournier T, Andrieux K. Assessment of dually labelled PEGylated liposomes transplacental passage and placental penetration using a combination of two ex-vivo human models: the dually perfused placenta and the suspended villous explants. Int J Pharm 2017; 532:729-737. [DOI: 10.1016/j.ijpharm.2017.07.076] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Revised: 07/25/2017] [Accepted: 07/26/2017] [Indexed: 12/18/2022]
|
35
|
Benavides M, Carrato A, Abad A, Guillen-Ponce C, Garcia-Alfonso P, Gil S, Cano Osuna M, Safont M, Gravalos C, Manzano-Mozo J, Sanchez A, Alcaide-Garcia J, López R, Massuti Sureda B, Sastre J, Martinez de Castro E, Escudero P, Méndez-Ureña M, Diaz Rubio E, Aranda Aguilar E. Impact of tumor location on the efficacy of first-line anti-EGFR monoclonal antibody plus chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC): Retrospective analyses of the randomized MACRO-2 and PLANET trials from TTD Group. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Gael Cordier A, Vibert F, Fournier T, Benachi A, Gil S. Impact of sickle cell disease (SCD) on human placenta development and functions. Placenta 2017. [DOI: 10.1016/j.placenta.2017.07.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Sastre J, de la Orden V, Martínez A, Bando I, Santamaría I, Bellosillo Paricio B, Palanca S, Peligros I, Mediero B, Llovet P, Moreno V, Viéitez J, Garcia-Alfonso P, Gil S, Ortiz Morales M, Salud Salvia M, Quintero G, Gesto F, Aranda Aguilar E, Diaz Rubio E. Circulating tumor cells (CTCs), molecular alterations and their correlation with characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated in the Spanish TTD VISNÚ Program. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Loturco I, Nakamura FY, Kobal R, Gil S, Pivetti B, Pereira LA, Roschel H. Traditional Periodization versus Optimum Training Load Applied to Soccer Players: Effects on Neuromuscular Abilities. Int J Sports Med 2016; 37:1051-1059. [PMID: 27706551 DOI: 10.1055/s-0042-107249] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
It is unknown whether traditional periodization of strength-power training involving accumulation, transformation and realization blocks is superior to other simpler and more practical training schemes. The purpose of this study was thus to investigate changes in strength/power/speed characteristics of elite soccer players in response to either classic strength-power periodization (TSP) or optimum power load (OPL). 23 professional soccer players were randomly assigned to TSP or OPL for 6 weeks in-season regular training (3 times per week). TSP involved half squats or jump squats, depending on the respective training block, while OPL involved only jump squats at the optimum power load. Results revealed that both groups presented similar significant (P<0.05) improvements in squat one repetition maximum, squat and countermovement jump heights and change of direction speed. In addition, although both groups reported significant increases in sprinting speed (P<0.05); delta change scores demonstrated a superior effect of OPL to improve 10- and 20-m speed. Similarly, OPL presented greater delta change in mean propulsive power in the jump squat. Therefore, training continuously at the optimum power zone resulted in superior performance improvements compared to training under classic strength-power periodization.
Collapse
Affiliation(s)
- I Loturco
- Sport Science, NAR - Nucleus of High Performance in Sport, São Paulo, Brazil
| | - F Y Nakamura
- Departamento de Educação Física, Universidade Estadual de Londrina, Londrina, Brazil
| | - R Kobal
- Department of Physical Education and Sport, University of São Paulo, São Paulo, Brazil
| | - S Gil
- NAR, Nucleus of High Performance in Sport, São Paulo, Brazil
| | - B Pivetti
- NAR - Nucleus of High Performance in Sport, NAR, São Paulo, Brazil
| | - L A Pereira
- Sport Science, NAR - Nucleus of High Performance in Sport, São Paulo, Brazil
| | - H Roschel
- Sport, University of Sao Paulo School of Physical Education and Sport, Sao Paulo, Brazil
| |
Collapse
|
39
|
Segond N, Chissey A, Guibourdenche J, Grosso A, Tsatsaris V, Gil S, Fournier T. Placental expression and role of lysyl oxidases (LOX) in the differentiation of human trophoblasts: A LOX Story? Placenta 2016. [DOI: 10.1016/j.placenta.2016.06.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
40
|
Affiliation(s)
- Paul Berveiller
- a Department of Gynecology and Obstetrics , Centre Hospitalier Intercommunal de Poissy Saint Germain , Poissy , France.,b GIG-EA 7404, UFR des Sciences de la Santé Simone Veil, Université Versailles Saint Quentin en Yvelines , Montigny-le-Bretonneux , France
| | - Sophie Gil
- c INSERM UMR-S 1139, Université Paris Descartes, Sorbonne Paris Cité , Paris , France.,d PremUp Foundation , Paris , France , and
| | - François Vialard
- b GIG-EA 7404, UFR des Sciences de la Santé Simone Veil, Université Versailles Saint Quentin en Yvelines , Montigny-le-Bretonneux , France.,e Department of Cytogenetic , Centre Hospitalier Intercommunal de Poissy Saint Germain , Poissy , France
| |
Collapse
|
41
|
Loturco I, Abad C, Nakamura FY, Ramos SP, Kobal R, Gil S, Pereira LA, Burini F, Roschel H, Ugrinowitsch C, Tricoli V. Effects of far infrared rays emitting clothing on recovery after an intense plyometric exercise bout applied to elite soccer players: a randomized double-blind placebo-controlled trial. Biol Sport 2016; 33:277-83. [PMID: 27601783 PMCID: PMC4993144 DOI: 10.5604/20831862.1208479] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2015] [Revised: 02/18/2016] [Accepted: 03/10/2016] [Indexed: 11/18/2022] Open
Abstract
The aim was to investigate the effects of far infrared (FIR) ray emitting clothes on indirect markers of exercise-induced muscle damage and physical performance recovery after a plyometric bout applied to soccer players. Twenty-one male players (18.9±0.6 years; 70.8±5.01 kg; 178.3±0.06 cm) performed 100 drop-jumps. Six hours after the bout, athletes put on FIR clothes (FIR) (density of 225 g·m-2, 88% far infrared rays emitting polyamide 66 Emana yarn (PA66) fibre, 12% Spandex, emissivity of 0.88 and power emitted of 341 W/m2µm at 37°C in the 5-20 µm wavelength range, patent WO 2009/077834 A2) (N = 10) or placebo clothes (PLA) (N = 11). Mid-thigh circumferences, creatine kinase (CK), and delayed-onset muscle soreness (DOMS) were assessed before, immediately after and 24, 48, and 72 h after the bout. Squat (SJ) and countermovement jump (CMJ) heights were measured before and at 24, 48, and 72 h after, while 1RM leg press (maximum strength) was measured before and at 72 h after the plyometrics. No differences between groups were found in mid-thigh circumferences, SJ, CMJ or 1RM. CK increased significantly 24 h after the plyometrics in comparison to before (p < 0.05) in both groups. PLA showed significant DOMS increases at 24, 48, and 72 h, while FIR showed significant increases at 24 and 48 h (p < 0.05). DOMS effect sizes were greater in FIR (moderate at 48 h, ES = 0.737 and large at 72 h, ES = 0.844), suggesting that FIR clothes may reduce perceived DOMS after an intense plyometric session performed by soccer players.
Collapse
Affiliation(s)
- I Loturco
- NAR - Nucleus of High Performance in Sport, São Paulo, SP, Brazil
| | - Ccc Abad
- NAR - Nucleus of High Performance in Sport, São Paulo, SP, Brazil
| | - F Y Nakamura
- State University of Londrina, Londrina, PR, Brazil
| | - S P Ramos
- State University of Londrina, Londrina, PR, Brazil
| | - R Kobal
- NAR - Nucleus of High Performance in Sport, São Paulo, SP, Brazil
| | - S Gil
- NAR - Nucleus of High Performance in Sport, São Paulo, SP, Brazil
| | - L A Pereira
- NAR - Nucleus of High Performance in Sport, São Paulo, SP, Brazil
| | - Fhp Burini
- Nutrition and Exercise Metabolism Center - UNESP, Botucatu, SP, Brazil
| | - H Roschel
- School of Physical Education and Sport, University of São Paulo, São Paulo, SP, Brazil
| | - C Ugrinowitsch
- School of Physical Education and Sport, University of São Paulo, São Paulo, SP, Brazil
| | - V Tricoli
- School of Physical Education and Sport, University of São Paulo, São Paulo, SP, Brazil
| |
Collapse
|
42
|
Gil S, Yébenes M, Luelmo J, Alsina M, Sabés M. A comparative study of the effectiveness of cisplatin and 5-fluorouracil on cutaneous squamous human carcinoma cell line: Potential chemotherapy alternative to surgery. Dermatol Ther 2016; 29:341-344. [PMID: 27292650 DOI: 10.1111/dth.12373] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Surgery as treatment for local invasive cutaneous squamous cell carcinoma (cSCC) is not always feasible due to the age and/or the health status of patients. Thus, the investigation of new strategies to improve the quality of life of them is required. The aim of this work is to investigate two chemotherapy agents individually on cSCC cells with the purpose to provide a better understanding of the effectiveness underlying each one. The cisplatin effectiveness is compared at different times with that observed for the 5-fluorouracil treatment. The effectiveness of both was assessed by using flow cytometry to determine the survival cell ratio, and QBlue test to study the cell recovery ability after treatments. A significant increase in the number of apoptotic cells, especially 48 hours after treatments, has been detected. Despite this, cisplatin arises as the most promising agent for the treatment of local invasive cutaneous squamous cell carcinoma due to the fact that a lower concentration and time are required to observe a higher effectiveness on cells with respect to the 5-fluorouracil. An optimal cisplatin-based chemotherapy might provide a better outcome for patients affected by a local invasive cSCC rather than surgery.
Collapse
Affiliation(s)
- S Gil
- Dermatology Department, Hospital Parc Taulí, Sabadell (Barcelona), Spain.
| | - M Yébenes
- Dermatology Department, Hospital Parc Taulí, Sabadell (Barcelona), Spain
| | - J Luelmo
- Dermatology Department, Hospital Parc Taulí, Sabadell (Barcelona), Spain
| | - M Alsina
- Dermatology Department, Hospital Clínic de Barcelona, Barcelona, Spain
| | - M Sabés
- Department of Biophysics, Faculty of Medicine, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), Spain
| |
Collapse
|
43
|
Abstract
In the present study, adults and children aged five and eight years were given a temporal bisection task involving emotional stimuli (angry and neutral faces) and three levels of discrimination difficulty that differed as a function of the ratio used between the short and the long standard duration (very easy, easy, and difficult). In addition, their cognitive capacities in terms of working memory and attention inhibition were assessed by neuropsychological tests. In the very easy temporal task (ratio of 1:4), the results showed that the psychophysical functions were shifted toward the left in all participants for the angry faces compared to the neutral faces, with a significant lowering of the Bisection Point, suggesting that the stimulus duration was judged to last longer for the emotional stimuli. In addition, the results did not show any relationship between the magnitude of this lengthening effect and individual cognitive capacities as assessed by the neuropsychological tests. The individual differences in working memory capacities only explained differences in sensitivity to time. However, when the difficulty of the temporal task increased, the children’s performance decreased and it was no longer possible to test for the emotional effect. Unlike the children, the adults were still able to discriminate time in the emotional task. However, the emotional effect was no longer observed. In conclusion, our study on temporal task difficulty shows the influence of available cognitive resources on the emergence of an emotional effect on time perception.
Collapse
Affiliation(s)
| | | | - S. Gil
- Université de Poitiers (CeRCA)France
| |
Collapse
|
44
|
Jovelet C, Broutin S, Gil S, Mir O, Paci A. [Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?]. Bull Cancer 2016; 103:478-83. [PMID: 26969425 DOI: 10.1016/j.bulcan.2016.02.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Revised: 01/22/2016] [Accepted: 02/08/2016] [Indexed: 02/09/2023]
Abstract
The association of cancer and pregnancy is increasingly frequent. This is related, partially, to the increasingly belated age of pregnancy. The management of cancer in pregnancy is a complicated issue. The use of tyrosine kinase inhibitors (TKIs) during pregnancy remains rare and only few data are available concerning their transplacental passage. The aim of this work is to review the data described in the literature, in order to highlight the risks incurred by the fetus, associated with these TKIs' treatment. Up to 189 pregnancies of women treated with TKIs during part or throughout their pregnancy have been described. Clinical data are reassuring and would be in favor of taking the treatment in terms of the balance maternal profit versus fetal risk. These data must, nevertheless, be interpreted with caution.
Collapse
Affiliation(s)
- Cécile Jovelet
- Gustave-Roussy, laboratoire de recherche translationnelle, 114, rue Edouard-Vaillant, 94805 Villejuif, France
| | - Sophie Broutin
- Gustave-Roussy, service de pharmacologie et d'analyse du médicament, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France
| | - Sophie Gil
- Université Paris Descartes, Inserm, UMR-S 1139, 4, avenue de l'Observatoire, 75006 Paris, France
| | - Olivier Mir
- Université Paris Sud, Gustave-Roussy, département de médecine oncologique, 114, rue Edouard-Vaillant, 94805 Villejuif, France
| | - Angelo Paci
- Gustave-Roussy, service de pharmacologie et d'analyse du médicament, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France.
| |
Collapse
|
45
|
Yousef I, Seksek O, Sulé-Suso J, Gil S, Prezado Y, Martínez-Rovira I. Infrared study of the biochemical effects in glioma cells induced by x-rays and Gd nanoparticles: first studies at SESAME synchrotron (Jordan). Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)30145-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
46
|
Alvarado-Martínez E, Costero AM, Gil S, Peña-Cabrera E. Sensing and discrimination of cyanide and hydrogen sulfide using an 8-alkenyl-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene derivative. RSC Adv 2016. [DOI: 10.1039/c5ra23307k] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
8-(2-Phenylethenyl)BODIPY has been shown to be an appropriate chromo-fluorogenic probe for cyanide in H2O.
Collapse
Affiliation(s)
| | - A. M. Costero
- Instituto Interuniversitario de Reconocimiento Molecular y Desarrollo Tecnológico Universitat de València. Dr Moliner
- Valencia
- Spain
- CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN)
- Spain
| | - S. Gil
- Instituto Interuniversitario de Reconocimiento Molecular y Desarrollo Tecnológico Universitat de València. Dr Moliner
- Valencia
- Spain
- CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN)
- Spain
| | - E. Peña-Cabrera
- Departamento de Química
- Universidad de Guanajuato. Col Noria Alta s/n
- Mexico
| |
Collapse
|
47
|
Muriel Lopez C, Perez-Ruiz E, Gonzalez I, Ales I, Pascual J, Duran G, Rivas-Ruiz F, Benavides M, Marquez A, Pajares B, Plata Y, Diaz T, Zarcos I, Alcaide J, Gimenez F, Lopez P, Gil S, Muros B, Rueda A, Alba E. 2304 Polychemotherapy on patients with pancreatic carcinoma: Experience of four hospitals in Spain. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31220-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
48
|
Abstract
El ácaro Varroa destructor es el principal problema de sanidad animal al que se enfrenta nuestra apicultura. La cuantificación de la población de este ácaro es un factor de gran importancia para la inspección veterinaria y los apicultores, además determina la necesidad de realizar o no realizar tratamientos. En este trabajo se evalúan diferentes métodos de diagnóstico: i) ácaros desprendidos con azúcar en polvo o etanol del cuerpo de abejas adultas barridas de cuadros de alimento y cría, ii) ácaros obtenidos de celdillas de cría de abejas obreras y iii) ácaros caídos a los fondos de las colmenas en un período de 4 días. El número de ácaros recogidos de los fondos de las colonias presenta una correlación positiva con el número total de ácaros presentes en las colonias. La cuantificación del número de ácaros presentes en las abejas adultas o en la cría de obrera solo puede ser utilizada de forma indicativa para el diagnóstico. El uso del azúcar en polvo solo desprende un tercio de los ácaros presentes en el cuerpo de las obreras adultas.
Collapse
|
49
|
|
50
|
Quilis N, Gil S, Andrés M, Vela P, Pascual E. FRI0327 Febuxostat Appears Effective and Safe in Gout Patients with Severe Chronic Kidney Disease:. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3320] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|